Zemplar Related Published Studies
Well-designed clinical trials related to Zemplar (Paricalcitol)
Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial. [2011.08.30]
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. [2010.11.06]
Effect of paricalcitol on the urinary peptidome of kidney transplant patients. [2010.10]
Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. [2010]
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. [2009.10]
Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. [2009.08]
Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use? [2009]
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. [2008.08]
Calcium balance during calcitriol and paricalcitol administration in healthy humans. [2008.03]
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. [2008]
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. [2007.06]
Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. [2007.03]
Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. [2006.07]
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. [2006]
Antiproteinuric effect of oral paricalcitol in chronic kidney disease. [2005.12]
Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. [2004.07]
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. [2003.04]
Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. [2001.11]
Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. [2001.11]
A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. [2001.10]
19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. [1998.08]
Well-designed clinical trials possibly related to Zemplar (Paricalcitol)
The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. [2011.04]
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. [2011.04]
Vitamin d receptor activators and clinical outcomes in chronic kidney disease. [2011]
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. [2011]
Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. [1998.10]
Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. [1998.10]
Other research related to Zemplar (Paricalcitol)
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment
of secondary hyperparathyroidism in patients receiving haemodialysis: results of
the IMPACT SHPT study. [2012]
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a
meta-analysis. [2012]
Converting to doxercalciferol capsules from intravenous paricalcitol or
doxercalciferol. [2012]
Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. [2011.12.01]
No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. [2011.10]
Exposure-Clinical Response Analysis of Paricalcitol in Patients With Chronic Kidney Disease (Stage 5) on Hemodialysis or Peritoneal Dialysis. [2011.09.22]
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. [2011.09.19]
Converting to Doxercalciferol Capsules From Intravenous Paricalcitol or Doxercalciferol. [2011.06.06]
The role of paricalcitol on proteinuria. [2011.06]
Paricalcitol in secondary hyperparathyroidism and the survival benefit in patients with chronic kidney disease. [2011.06]
Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study. [2011.04]
Calcific uremic arteriolopathy treated with cinacalcet, paricalcitol, and autologous growth factors. [2011.03]
Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. [2011.03]
Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. [2011.01]
The impact of paricalcitol on left ventricular hypertrophy. [2011]
Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. [2011]
No difference between alfacalcidol and paricalcitol in the treatment of secondary
hyperparathyroidism in hemodialysis patients: a randomized crossover trial. [2011]
Paricalcitol, a synthetic vitamin D analog: a candidate for combination therapy with biological agents in rheumatoid arthritis. [2010.12]
The unsolved cyclosporine-induced kidney injury: is paricalcitol a feasible new renoprotective option? [2010.06]
Paricalcitol attenuates cyclosporine-induced kidney injury in rats. [2010.06]
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. [2010.06]
Use of 3-hour daily hemodialysis and paricalcitol in patients with severe secondary hyperparathyroidism: A case series. [2010.04]
Pivotal role of paricalcitol in the treatment of calcific uremic arteriolopathy in the presence of a parathyroid adenoma. [2010.01]
Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. [2010]
Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. [2010]
Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. [2009.12]
Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. [2009.09.24]
Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". [2009.06]
Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. [2009.05]
Paricalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients on Sevelamer Hydrochloride: Which Dialysate Calcium Concentration to Use? [2009.01.14]
Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. [2009.01]
Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. [2009]
Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. [2008.11]
Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study. [2008.10]
Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. [2008.09]
Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calciphylaxis with hyperparathyroidism. [2008.08]
Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. [2008.04]
Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. [2008.04]
The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. [2008.02]
Paricalcitol treatment and arterial tone in experimental renal insufficiency. [2008]
Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis or Peritoneal Dialysis. [2007.10.03]
Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. [2007.10]
Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan. [2007]
Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism. [2007]
Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. [2007]
Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. [2006.12]
Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. [2006.10]
Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease. [2006.05]
Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. [2006.05]
Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease. [2006.04]
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. [2006.02]
The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar). [2006]
Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. [2006]
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. [2005.12.15]
Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. [2005.11]
Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. [2005.11]
Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. [2005.06]
Spotlight on paricalcitol in secondary hyperparathyroidism. [2005]
Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. [2005]
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. [2004.05]
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. [2003.07.31]
Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients. [2003.06]
Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up. [2003]
Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. [2001.11]
A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. [2001.10]
Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. [2000.10]
Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. [1999.03]
Other possibly related research studies
[New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics] [2005]
Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs? [2005.03]
19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. [2005.03.15]
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. [2005.04]
Are new vitamin D analogues in renal bone disease superior to calcitriol? [2005.03]
Vitamin D analogs as therapeutic agents: a clinical study update. [2004.03]
Calcimimetics versus vitamin D: what are their relative roles? [2004]
|
